Allosteric control sites in KRAS protein found
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
List view / Grid view
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
Proximity labelling and single-particle tracking demonstrated that effectors in bacteria bind to mobile injectisome components.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly…
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
Intestinal organoids allowed researchers to understand how Rnf43 and Daam1 influence the balance of stem cell renewal and differentiation.
A discovery about the mutated protein DECTIN-1, that limits the production of T regulatory cells, could lead to more effective drugs.
By mapping the genome, scientists have discovered how IKAROS enables differentiation of hematopoietic stem cells into B cells.
An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Crosslinking damage to single stranded RNA, caused by aldehydes, is repaired by newly discovered mechanism involving ribosomes.